Title

Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire

Download PDF

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use

Download PDF

Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary

Download PDF

Charleston Laboratories, Inc. Expands Senior Management Team with Two Key Appointments in Core Business Areas of Medical & Commercialization

Download PDF

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108

Download PDF

Charleston Laboratories, Inc. Announces Presentations at the Annual Scientific Meeting of the American Pain Society

Download PDF

Governor Scott Announces Charleston Laboratories, Inc. Expansion Will Create 25 New Jobs

Download PDF

The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion

Download PDF

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints

Download PDF

Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board

Download PDF

Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston’s Second Product, CL-H1T

Download PDF

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting

Download PDF

Charleston Laboratories, Inc. Completes Patient Enrollment in a Phase 3

Download PDF

Charleston Laboratories, Inc. & Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108

Download PDF

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston’s Lead Product, CL-108

Download PDF

Prescription for Success

Download PDF

Charleston Laboratories, Inc.  Announces Key Clinical Updates for Novel Drugs

Download PDF

Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US

Download PDF

Charleston Laboratories, Inc., Bolsters Senior Management Team

Download PDF

Charleston Laboratories, Inc. Announces Publication of Abstract for CL-108 Phase 3 Study at APS 2014

Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain

Download PDF

Charleston Laboratories, Inc. Announces Research Collaboration with Stanford University

Download PDF

Charleston Laboratories, Inc Successfully Completes Pre-IND Meeting on New Migraine Treatment

Download PDF

FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment

Download PDF

Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial

Download PDF

Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant

Download PDF

Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108

Download PDF

Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

Download PDF

Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ)

Download PDF

Charleston Labs begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108

Download PDF

Charleston completes successful Type B, Pre-IND meeting with FDA’s Division of Anesthesia, Analgesia and Rheumatology Products on November 8, 2007, held at FDA’s Silver Spring, Maryland offices.

Download PDF